Posted on October 15, 2010 by Sitemaster
According to a media release issued on Thursday this week by Molecular Insight Pharmaceuticals, Inc. (MIP), an investigational imaging agent known as Trofex™ (a.k.a, 123I-MIP-1072) may offer a new opportunity to identify the presence of early signs of metastatic prostate cancer in the prostate bed, soft tissues, and bone within 4 hours after injection. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk | Tagged: 123I-MIP-1072, agent, imaging, PMSA, Trofex | 2 Comments »
Posted on June 17, 2009 by Sitemaster
According to a company press release, Molecular Insight Pharmaceuticals, Inc. presented clinical data earlier today on a development-stage, radiolabeled, small-molecule, molecular imaging pharmaceutical with potential in the diagnosis, staging, and perhaps even the treatment of advanced forms of prostate cancer. … READ MORE …
Filed under: Diagnosis, Management, Risk, Treatment | Tagged: Diagnosis, metastatic, prostate cancer, staging, Treatment, Trofex | 6 Comments »
